Figure 8: Relative cytotoxic anti-neoplastic potency of gemcitabine in dual combination griseofulvin compared to gemcitabine alone against chemotherapeutic-resistant mammary adenocarcinoma. Legend: (■) gemcitabine with griseofulvin; (♦) gemcitabine alone; and (▲) gemcitabine- (C4-amide)-[anti-HER2/neu] with griseofulvin. Chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) monolayer populations were incubated for 182-hours with gemcitabine (+/- grisofulvin 15 ΜM fixed-concentration) formulated in triplicate at gradient concentrations. Cytotoxic anti-neoplastic potency was measured using a MTT cell vitality assay relative to matched negative reference controls.